2nd Part got cut off for some reason:
https://erj.ersjournals.com/content/erj/32/5/1141.full.pdf
In essence we are at a clinically significant, but statistically insignificant junction. Nobody can tell u whether its 60/40 or 25/75.
The risk reward though is definitely biased to the upside! (if it all falls through msb goes back to $2 at worst vs a whole range of exciting outcomes even if the next tier of results are even half as good).
Though admittedly I will be selling some if it opens near the $5 US levels as I believe the there will be some profit taking, and there has not been any new development between the Aus close and US open to justify the premium.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-493
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
0.620(34.6%) |
Mkt cap ! $3.084B | |||
| Open | High | Low | Value | Volume |
| $1.90 | $2.48 | $1.90 | $58.82M | 25.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 100915 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 99 | 1 |
View Market Depth
| Last trade - 16.12pm 18/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |